NCT02107599View on ClinicalTrials.gov

The Feasibility of Florbetapir Quantitation in Europe

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Alzheimer's Disease
Interventions
DRUG

Florbetapir (18F)

No Florbetapir (18F) will be administered in this study.

Trial Locations (1)

2316XC

Research Site, Leiden

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY